Bellerophon Therapeutics (NASDAQ:BLPH) Earns Hold Rating from Analysts at StockNews.com

Analysts at StockNews.com started coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a report released on Wednesday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

BLPH stock opened at $0.06 on Wednesday. The stock has a market cap of $684,880.00, a P/E ratio of -0.07 and a beta of 0.69. The stock’s fifty day simple moving average is $0.06 and its two-hundred day simple moving average is $0.05. Bellerophon Therapeutics has a 1-year low of $0.03 and a 1-year high of $11.15.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.